The mpox vaccine from Bavarian Nordic was authorized by the World Health Organization (WHO) on Monday for use in adolescents between the ages of 12 and 17, who are thought to be particularly susceptible to outbreaks of the disease that have raised concerns throughout the world.
In a statement, the WHO stated that on October 8, it prequalified the Jynneos vaccine for use in adolescents.
In August, a new strain of the virus spread from the Democratic Republic of the Congo to its neighbors, prompting the World Health Organization to designate mpox a worldwide public health emergency for the second time in two years.
In September, the United Nations agency authorized the vaccination as the first line of defense against mpox in adults, facilitating better access to the vaccine for severely affected African nations.
